CN

CN
Steve Yang, Ph.D
Co-CEO
A pharmaceutical industry leader recognized for building R&D and service capabilities, delivering research and early development portfolios of drug candidates, and establishing R&D partnerships in US, Europe, China and other Asian and emerging markets. Before joining WuXi, Dr. Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, and served as Vice President and Head of Asia R&D at Pfizer and as Executive Director and head of Pfizer's global R&D strategic management group. Dr. Yang received his PhD in Pharmaceutical Chemistry from the University of California, San Francisco.
Tao Guo, Ph.D
Senior Vice President, Head of International Discovery Service Unit
Over 20 years’ experience in organic/medicinal chemistry, formerly Director of Chemistry at Pharmacopeia. B.S. in Chemistry from Peking University, Ph.D in Organic Chemistry from Columbia University, and postdoctoral fellow in Bioorganic Chemistry at UC Berkeley.
Qunsheng Ji, Ph.D
Vice President, Head of Oncology and Immunology Unit
Over 15 years of industry experience in drug discovery and translational science especially in oncology and recently renal diseases. Ph.D from Chinese Academy of Medical Science/ Peking Union Medical College, jointed with Vanderbilt University USA, Medical degree from First Military Medical University in Guangzhou.
Henry Lu, Ph.D
Vice President, Head of Biology
Over 20 years’ experience in biological research and pharmaceutical industry. Formerly Adjunct Associate Professor at the University of California San Francisco, Senior Director of Infectious Diseases at Rigel Pharmaceuticals Inc. B.S. from Fudan University, Ph.D from the Shanghai Institute of Biochemistry, Academia Sinica.
Baoning Su, Ph.D
Vice President, Head of Core Analytical Services (CAS) Unit
Over 20 years working experience in the areas of natural products and pharmaceutical analyses, formerly Senior Research Investigator at Bristol-Myers Squibb. Ph.D in Organic Chemistry from Lanzhou University.
Xuanjia Peng, Ph.D
Vice President, Head of HitS unit
Over 15 years’ experience in organic/medicinal chemistry, rich experience on small molecule drug discovery and successively led the medicinal chemistry group, CSU operation team, LabNetwork team, and DWL team to achieve rapid growth and empower numerous clients from small start-ups to world-class global customers.
Peiyuan Lin, PH.D
Senior Vice President, HD Biosciences
Peiyuan Lin joined HD Biosciences (Wuxi subsidiary company) as Senior VP in 2008, leading R&D efforts in drug discovery. Peiyuan Lin earned her Ph.D. in molecular pharmacology from the University of Cincinnati College of Medicine in 1988. Since then, she has gained extensive knowledge and experience working internationally over the last 30 years in both Pharmaceutical Drug Discovery and the CRO industry.
Declan Ryan, Ph.D
Vice President, US Business Development
Over 20 years' experience in R&D in both research and business development roles at 3-Dimensional Pharmaceuticals, Novartis, Johnson & Johnson, AMRI and Shanghai ChemPartner. Ph.D from University of Lausanne, Switzerland and Post-doc studies at Yale University and University of Pittsburgh, USA.
Dave Madge, Ph.D
Vice President, Research Service Division
Over 20 years’ experience working within academia, biotech and CROs. Former VP Research at Xention, founder of NCE Discovery (now Domainex) and a member of the integrated biomedical research group at University College London. Dave started his career at the Wellcome Foundation and received his Ph.D in Chemistry from Imperial College, London.